-
Precio de kits ELISA: rangos reales y coste por ensayo(Post)
Precio de kits ELISA: rangos reales y coste por ensayo El precio de un kit ELISA de 96 pocillos varía considerablemente según el fabricante, la validación y la aplicación, con ejemplos que muestran v
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Car t signalling pathway · H(Page) Apoptosis Unveiled: Your Complete Guide to Intrinsic & Extrinsic Pathways(Post)Cell Biology · Programmed Cell DeathApoptosis: Your Complete Guide to Intrinsic & Extrinsic PathwaysApoptosis is programmed cell death — the controlled, non-inflammatory removal of damaged or unwanted
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research(Post)Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
miRNAs as therapeutics and biomarkers for pancreatic cancer(Post)Pancreatic cancer survival rates Despite recent advances in our understanding of this disease, pancreatic cancer is one of the world’s most lethal malignan
PI3K/AKT/mTOR Signalling in T Cells: Pathway, Function and Assays(Post)PI3K does not switch on a protein — it rewrites a membrane. Everything downstream follows from one chemical event: the 3-hydroxyl of a phosphoinositide is phosphorylated, PIP₂ becomes PIP₃, and every
Coronavirus Assays(Page)Coronavirus Assays | SARS-CoV-2 ELISA, Multiplex, Rapid & PCR | Assay Genie
T-cell receptor (TCR) signalling(Page) AKT Signalling – Mini Review(Post)Protein kinase B or AKT (PKB) is a serine/threonine kinase. In mammals it is comprised of 3 highly homologous isoforms PKBα (Akt1), PKBβ (Akt2), and PKBγ (Akt3) (Manning and Cantley 2007). AKT
Vascular Endothelial Growth Factor A (VEGFA): A Cornerstone in Angiogenesis and Beyond(Post)Vascular Endothelial Growth Factor A (VEGFA) is a pivotal signaling protein involved in both vasculogenesis and angiogenesis, processes essential for the formation of blood vessels during embryoni
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Autophagy alterations in Alzheimer’s disease(Post)By Diana-Madalina Stan, PhD student, University of Salford Disease Description Alzheimer’s disease (AD), the most common cause of dementia, is a neu
Pamrevlumab: Unveiling the Potential of Anti-Fibrotic Therapy in Clinical Trials and Research(Post)Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver of
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
EGF Family (Post)Epidermal Growth Factor (EGF) is a protein that stimulates cell growth and differentiation by binding to its receptor epidermal growth factor receptor (EGFR) which triggers ligand-induced d